Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
Donna Grogan, a non-employee director of C4 Therapeutics, Inc. (CCCC), received 6,740 shares of common stock on 10/01/2025 by electing to take equity in lieu of cash under the company’s Non-Employee Director Compensation Policy. The shares were recorded at a per-share price of $2.15, equal to the closing market price on the transaction date. After the grant, the reporting person beneficially owned 58,629 shares, held directly. The Form 4 discloses the transaction code and confirms the shares were issued as director compensation.
C4 Therapeutics, Inc. announced on October 1, 2025 that it entered a clinical trial collaboration and supply agreement with Pfizer. Under the agreement, Pfizer will supply elranatamab (ELREXFIO®), a BCMAxCD3 bispecific antibody, at no cost for C4's upcoming Phase 1b trial testing the safety and tolerability of cemsidomide plus dexamethasone in combination with elranatamab for patients receiving second-line or later therapy for multiple myeloma. C4 will sponsor and run the trial while Pfizer will receive access to trial data. The company furnished a press release as Exhibit 99.1 to the current report.
C4 Therapeutics, Inc. (CCCC) reported that it issued a press release and presented clinical data from its Phase 1 trial of cemsidomide plus dexamethasone for relapsed/refractory multiple myeloma at the International Myeloma Society (IMS) Meeting in an oral presentation on September 20, 2025. The company furnished the press release as Exhibit 99.1 and posted the presentation slides on its investor relations site, filing those slides as Exhibit 99.2 to this Current Report on Form 8-K. The filing states these materials are "furnished" (not "filed") and does not include financial results or detailed trial outcomes within the Form text. The company also notes the furnishing does not constitute an admission as to materiality.
C4 Therapeutics, Inc. (CCCC) reported that it issued a press release and presented clinical data from its Phase 1 trial of cemsidomide plus dexamethasone for relapsed/refractory multiple myeloma at the International Myeloma Society (IMS) Meeting in an oral presentation on September 20, 2025. The company furnished the press release as Exhibit 99.1 and posted the presentation slides on its investor relations site, filing those slides as Exhibit 99.2 to this Current Report on Form 8-K. The filing states these materials are "furnished" (not "filed") and does not include financial results or detailed trial outcomes within the Form text. The company also notes the furnishing does not constitute an admission as to materiality.
C4 Therapeutics insider filing: The reporting person, Kendra Adams (CFO), acquired 6,250 shares of common stock on 09/18/2025 upon vesting of previously granted restricted stock units (RSUs). The shares were issued at no cash price upon vesting and increased her beneficial holdings to 165,117 shares. In connection with the vesting, the issuer withheld 2,775 shares to satisfy tax withholding obligations, which reduced the net shares delivered and left 162,342 shares listed after the withholding entry on the Form 4.
C4 Therapeutics insider filing: The reporting person, Kendra Adams (CFO), acquired 6,250 shares of common stock on 09/18/2025 upon vesting of previously granted restricted stock units (RSUs). The shares were issued at no cash price upon vesting and increased her beneficial holdings to 165,117 shares. In connection with the vesting, the issuer withheld 2,775 shares to satisfy tax withholding obligations, which reduced the net shares delivered and left 162,342 shares listed after the withholding entry on the Form 4.
C4 Therapeutics (NASDAQ: CCCC) Q2 2025 10-Q highlights
- Revenue: $6.5 m from collaborations, down 46 % YoY (Q2 24: $12.0 m) as Biogen–related income rolled off.
- Expenses: R&D $26.2 m (+10 % YoY); G&A $8.8 m (-10 % YoY). Total op-ex $35.0 m (+4 %).
- Losses: Operating loss widened to $28.5 m; net loss $26.0 m (-$0.37 pps) versus $17.7 m (-$0.26 pps) a year ago. 1H 25 net loss $52.3 m.
- Cash runway: Cash, cash equivalents & marketable securities were $223 m at 6-30-25 (vs. $267 m at 12-31-24); management projects ≥12-month runway.
- Balance sheet: Deferred revenue $43.8 m, reflecting future work under Roche, MKDG, Merck and Betta deals; no debt.
- Collaboration momentum: Earned $1 m discovery milestone (MKDG) and two $2 m lead-series milestones (Roche). Q2 revenue mix: MKDG 53 %, Roche 30 %, Merck 16 %, Betta 1 %.
- Share count: 71.2 m outstanding (7-29-25) after equity comp and ESPP; authorized shares doubled to 300 m.
- Guidance & risk: Company remains clinical-stage with no product sales; relies on external funding and partner milestones; accumulated deficit $686 m.
The filing affirms strategic focus on protein-degrader oncology programs (e.g., CFT8919, DACs) while controlling G&A. Near-term catalysts hinge on progress within partnered pipelines and internal Phase 1 assets.